A large clinical trial evaluating high dose biotin (MD1003, Qizenday) in secondary and primary progressive MS has failed to show that the treatment leads to improvements in disability.
Topline results from the study have been announced in a press release from the manufacturer, MedDay. Detailed results of the study will be presented at the American Academy of Neurology (AAN) meeting in Toronto, April 2020.
About the study
The SPI2 trial evaluated the safety and effectiveness of three daily doses of 100mg of high dose biotin compared to placebo in 642 people with progressive MS without recent relapses, also called non-active progressive MS. The main measure of the study was an improvement in disability, which could be either a lower EDSS score or a reduction in the time to walk 25 feet. There was no improvement in either of these measures in comparison to the placebo group.
MD1003 is a highly concentrated formulation of biotin which has been undergoing clinical studies.
An earlier clinical trial (MS-SPI) which recruited 154 participants with progressive MS had provided initial evidence that high doses of biotin might have an impact on disability and progression. The main measure of the study was improvement in disability after 9 months of treatment which was still evident at 12 months. Improvement in disability could be either a reduction in EDSS or a reduction in the time to walk 25 feet. Slightly less than 13% of the MD1003 group and none of the placebo group met this criteria.
Biotin, also known as vitamin H or coenzyme R, is one of the B-group vitamins (vitamin B7). It is involved in a wide range of cell processes. It has been suggested that very high doses of biotin may be effective in MS by promoting myelin repair through activation of an enzyme involved in myelin synthesis and by enhancing energy production in demyelinated nerves.
Kesimpta (ofatumumab) approved for relapsing remitting MS in Scotland
12 Jul 2021 - 00:00
The MS Trust is delighted that Kesimpta (ofatumumab) has been approved by SMC for people with active relapsing remitting multiple sclerosis.
Stem cell transplants in the news
5 Jul 2021 - 00:00
Difficulties accessing NHS stem cell transplants (also known as HSCT or AHSCT) for multiple sclerosis were highlighted in national newspapers this weekend.
MS onset in childhood: do disease modifying drugs delay long term disability?
17 Jun 2021 - 00:00
Researchers have investigated how the risk of developing long term disability has changed over the last three decades for people whose MS begins in childhood.
With a little help from my furry friend
21 Jul 2021 - 00:00
Lisa, who was diagnosed with MS in 2008 tells us about how creativity and a little help from Spud the hamster helped her get through tougher times.
People with MS thoughts on freedom day
19 Jul 2021 - 00:00
From Monday the 19th of July, most covid restrictions have been lifted in England but what are people with MS really feeling about the so called "Freedom day"?
In this article we talk to some people with MS about their feelings, plus we cover what you can do if you are worried about the lifting of restrictions.
Just keep wheeling
14 Jul 2021 - 00:00
Emily, also known as The Wibbly Dinosaur, discusses her feelings on mobility aids and how using a wheelchair provides her with the freedom to continue doing the things she enjoys.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.